Acarix Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Aamir Mahmood

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Aamir Mahmood (47 yo)

less than a year

Permanencia

Mr. Aamir Mahmood serves as President and Chief Executive Officer of Acarix AB (publ) since February 1, 2024. He serves as General Manager/Vice President Americas of MicroPort CRM. He has experience in cor...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Aamir Mahmood	President & Chief Executive Officer	less than a year	sin datos	sin datos
Claus Bo Christensen	Founder and Interim Head of R&D	no data	sin datos	0.025% SEK 59.4k
Christian Lindholm	CFO & Executive VP	8.3yrs	kr2.28m	0.0052% SEK 12.1k
Thomas Borch	Interim Chief Operating Officer	less than a year	sin datos	sin datos
Jennifer Anderson	Head of Marketing & Communication	2.3yrs	sin datos	sin datos
Jennifer Matson	Head of Medical Affairs	2.3yrs	sin datos	sin datos
Carma Connely	Head of Market Access & Customer Excellence	2.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ACARIX se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Philip Siberg	Independent Chairman of the Board	3yrs	kr526.00k	0.025% SEK 59.4k
Fredrik Buch	Independent Director	3yrs	kr263.00k	0.071% SEK 167.0k
Louise Janssen-Counotte	Independent Director	4yrs	kr263.00k	sin datos
Ulf Rosén	Independent Director	10.3yrs	kr220.00k	0.61% SEK 1.4m
David Erlinge	Member of Clinical Advisory Board	no data	sin datos	sin datos
Morten Bottcher	Member of Clinical Advisory Board	no data	sin datos	sin datos
Peter Clemmensen	Member of Clinical Advisory Board	no data	sin datos	sin datos
John Cleland	Member of Clinical Advisory Board	no data	sin datos	sin datos
Mikael Thorén	Independent Director	less than a year	kr154.00k	sin datos
Deepak Talreja	Medical Advisor	less than a year	sin datos	sin datos
Saumil Oza	Member of the Advisory Board	less than a year	sin datos	sin datos
Dave Braun	Member of the Advisory Board	less than a year	sin datos	sin datos

2.0yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de ACARIX no se considera experimentada (1.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Acarix Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Acarix Appoints New Members to the Advisory Board

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Recent updates

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

New 90-day low: kr1.12

Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study

Acarix Receives US Market Approval for the CADScor System

New 90-day high: kr1.29

Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR

Third quarter 2020 earnings released: kr0.11 loss per share

Acarix AB (publ) to Report Q1, 2021 Results on May 11, 2021

New 90-day high: kr1.22

Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million.

New 90-day low - kr0.73

Acarix AB (publ) to Report Q4, 2020 Results on Feb 18, 2021

Earnings released

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad